VolitionRx Limited (NYSE American: VNRX) has announced a collaboration with Sysmex (TYO: 6869) to optimize Volition's Nu.Q® NETs H3.1 assay on the Sysmex diagnostic platform. The agreement supports Volition's strategy of licensing its proprietary Nu.Q® NETs technology to established global diagnostics companies that can leverage their disease expertise, regulatory capabilities and installed analyzer base to accelerate development and commercialization.
Volition said the collaboration has progressed beyond assay transfer and into the optimization phase for diseases associated with NETosis, a process implicated in conditions including sepsis and other acute and chronic diseases. The company believes the Nu.Q® NETs assay could provide improved diagnostic information, support patient monitoring and address a commercial opportunity with an estimated total addressable market of $3.8 billion.
NETosis is a cell death process that can lead to the formation of neutrophil extracellular traps (NETs), which are implicated in various inflammatory and thrombotic conditions. The Nu.Q® NETs assay targets H3.1, a specific marker of NETosis, potentially enabling earlier detection and better monitoring of diseases such as sepsis. Sepsis alone is a leading cause of death worldwide, and improved diagnostics could significantly impact patient outcomes.
For business leaders, this collaboration represents a strategic move by Volition to monetize its technology through partnerships rather than direct commercialization. By leveraging Sysmex's global reach and established diagnostic platforms, Volition can accelerate market entry without bearing the full cost of development and regulatory approval. This model reduces risk and capital expenditure while tapping into a large addressable market.
The diagnostics industry is increasingly focused on biomarker-driven tests that enable precision medicine. The Nu.Q® NETs assay fits this trend, offering a potential tool for not only diagnosis but also monitoring disease progression and treatment response. For healthcare providers and payers, such assays could lead to more efficient resource allocation and improved patient management.
Volition is a multi-national company focused on advancing the science of epigenetics. Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis.
The collaboration with Sysmex is a key step in Volition's strategy to bring its Nu.Q® NETs technology to market. As the optimization phase progresses, further announcements regarding clinical validation and regulatory submissions are anticipated. The success of this partnership could pave the way for additional licensing deals, strengthening Volition's position in the diagnostics space.
For more information, visit the company's website at https://volition.com/.
